Bringing the Oncology Community Together

March Net Guide: Melanoma

Published Online: Thursday, April 7, 2011


Sentinel Node Biopsy Illustrated in Video

A clear, comprehensive video produced by the Mayo Clinic illustrates the procedure for determining whether cancer has spread to the lymph nodes through biopsy of the sentinel nodes, the first node that filters lymph fluid draining from the melanoma.

Before surgery, a radioactive material is injected into the skin around the site of the original melanoma. The radioactive substance travels through the lymph channels and collects in the sentinel node. Blue dye makes the sentinel node even more apparent.

Once the node is removed, it can be sliced and tested for melanoma cells. The Online Oncologist


A Place of Comfort and Reassurance

Hosted through the Melanoma Research Foundation, the “Melanoma Patients Information Page” provides support and information to caregivers, patients, family, and friends.

Recent posts on the bulletin board run the gamut from “Just diagnosed … a little scared” to “One more round to go.” Replies offer advice and reassurance. The bulletin board is just one feature on a page chockfull of news, resources, and links to features such as a chat room and a page of memorials. The Educated Patient


Rampant Underreporting of Melanoma Is Found

Malignant melanoma may be far more prevalent than current statistics indicate because of pervasive underreporting to cancer registries nationwide, according to results of a small survey reported at the annual meeting of the American Academy of Dermatology (AAD) in February.

Seema P. Kini, MD, a researcher at Emory University in Atlanta, Georgia, found that 58% of dermatologists who completed the survey did not report new cases to cancer registries, and 50% were not aware they are required by law to do so. Dermatologists with <10 years’ experience were 3.3- fold more likely to be unaware of the reporting rules. The results were drawn from the answers of 104 dermatologists who responded to a survey during the AAD conference last year.


Dermoscopy of Nevi and Melanoma in Childhood


FEE: None

EXPIRES: February 7, 2012

Intended for primary care clinicians, dermatologists, pediatricians, and other health professionals caring for children with melanocytic lesions, this activity focuses on how dermoscopy can help clinicians identify and manage those lesions.

The authors examine the clinical morphology of melanocytic nevi and melanoma in the pediatric population, and describe the relevant dermoscopic findings and histopathologic correlates that aid in diagnosis and management.

Participants will learn to describe the potential advantages and disadvantages of dermoscopy of melanocytic lesions in children; discuss how dermoscopy can help differentiate benign from malignant lesions; address how dermoscopy can facilitate workup and management of the lesions; and describe classification of the lesions. Melanoma CME


Study of Individuals and Families at High Risk for Melanoma

STUDY TYPE: Observational

AGE/SEX REQUIREMENTS: up to 95 years (none)

SPONSOR: National Cancer Institute


PURPOSE: This study seeks to identify genetic and environmental factors related to melanoma risk in individuals and families in danger of developing melanoma. Among its objectives are evaluating and defining the clinical spectrum and natural history of disease in syndromes predisposing individuals and families to melanoma; mapping, cloning, and determining the function of tumor susceptibility genes in melanoma-prone families; and quantifying risks of melanoma, pancreatic cancer, and other cancers in family members. It will also educate and counsel study participants about their melanoma risk and identify means of prevention. Estimated completion date is December 2012. Clinical Trials

Related Articles
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
T-VEC Promotes Tumor Shrinkage in Unresectable Melanoma
The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions
Nivolumab Delivers Durable Remissions With Low Toxicity in Advanced Melanoma
Nivolumab, a PD-1-specific antibody, has been shown to produce long-term remissions with limited toxicity in patients with advanced melanoma, according to results from one of the longest follow ups to examine the drug.
New Paradigms Emerge for Translating Immunotherapy Into Broad Clinical Use
Although breakthrough successes are generating a renaissance for anticancer immunotherapies, the framework for translating promising research results into clinical practice remains very much under construction.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.